Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCastella, Maria-
dc.contributor.authorBoronat, Anna-
dc.contributor.authorMartín-Ibáñez, Raquel-
dc.contributor.authorRodríguez, Vanina-
dc.contributor.authorSuñé, Guillermo-
dc.contributor.authorCaballero, Miguel-
dc.contributor.authorMarzal, Berta-
dc.contributor.authorPérez-Amill, Lorena-
dc.contributor.authorMartín-Antonio, Beatriz-
dc.contributor.authorCastaño, Julio-
dc.contributor.authorBueno, Clara-
dc.contributor.authorBalagué, Olga-
dc.contributor.authorGonzález-Navarro, Europa Azucena-
dc.contributor.authorSerra Pagès, Carles-
dc.contributor.authorEngel Rocamora, Pablo-
dc.contributor.authorVilella, Ramon-
dc.contributor.authorBenítez Ribas, Daniel-
dc.contributor.authorOrtiz-Maldonado, Valentín-
dc.contributor.authorCid Vidal, Joan-
dc.contributor.authorTabera, Jaime-
dc.contributor.authorCanals i Coll, Josep M.-
dc.contributor.authorLozano, Miquel-
dc.contributor.authorBaumann, Tycho-
dc.contributor.authorVilarrodona, Anna-
dc.contributor.authorTrias, Esteve-
dc.contributor.authorCampo Güerri, Elias-
dc.contributor.authorMenendez, Pablo-
dc.contributor.authorUrbano Ispizua, Álvaro-
dc.contributor.authorYagüe, Jordi-
dc.contributor.authorPérez Galán, Patricia-
dc.contributor.authorRives, Susana-
dc.contributor.authorDelgado, Julio-
dc.contributor.authorJuan, Manel-
dc.description.abstractGenetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo, A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg-Prkdcscid Il2rdtm1Wjl/SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients.-
dc.format.extent11 p.-
dc.publisherCell Press-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofMolecular Therapy-Methods & Clinical Development, 2018, vol. 12, p. 134-144-
dc.rightscc-by (c) Castella, Maria et al., 2018-
dc.subject.classificationCèl·lules T-
dc.subject.otherT cells-
dc.titleDevelopment of a novel anti-CD19 chimeric antigen receptor: A paradigm for an affordable CAR T cell production at academic institutions-
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
684889.pdf2.03 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons